

Fig. S1. Incidence of new systemic treatments prescribed each year from 2017 until 2022.

Legend: Year of introduction of new systemic treatments in the Netherlands (based on the approval dates of the European Medicines Agency(37): dupilumab, 2017 Q3; tralokinumab, 2021 Q2; baricitinib, 2020 Q3; Q2; upadacitinib, 2021 Q3; abrocitinib, 2021 Q4.




Fig. S2. Treatment patterns from initial to second advanced systemic treatment.

Legend: Advanced systemic treatments include dupilumab, tralokinumab, abrocitinib, baricitinib and upadacitinib. Switchers, non-switchers and discontinuation of treatment is analysed in percentages. Dupilumab is the most frequently prescribed initial advanced systemic treatment, and the majority of patients were found to remain on dupilumab (287, 60%). Tralokinumab and abrocitinib were less frequently prescribed as initial advanced systemics. Patients who started baricitinib had the highest rates of switching to other treatments (73%).

